"In chaos, there is fertility." - Anais Nin
Today, we revisit Global Blood Therapeutics (GBT). This stock has had an up and down year as can be seen from the chart below.
The shares have recently been on an upswing despite the current horrid sentiment in the market. The company just posted encouraging late-stage trial results, has potential catalysts on the horizon, and is seeing a big uptick in positive analyst commentary. We revisit this promising small-cap concern in the paragraphs below.
Company Overview
Global Blood Therapeutics is a San Francisco-based